PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression
Journal for ImmunoTherapy of Cancer · 2023-11 · 11 (11) · e007627
DOI: 10.1136/jitc-2023-007627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.11.2023. Verfasst von Zhiwei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Talents · Innovation Leading Talents Project, Natural Science Foundation of Chongqing, China.
Abstract (Originalsprache)
Background
Programmed death-ligand 1 (PD-L1) contributes to the immune escape of tumor cells and is a critical target for antitumor immunotherapy. However, the molecular mechanisms regulating PD-L1 expression remain unclear, hindering the development of effective therapies. Here we investigate the role and molecular mechanism of the core clock gene Period2 (PER2) in regulating PD-L1 expression and its role in the combination therapy of oral squamous cell carcinoma (OSCC).
Methods
Quantitative real-time PCR, western blotting or immunohistochemistry to detect expression of PER2 and PD-L1 in OSCC tissues and cells. Overexpression and knockdown of PER2 detects the function of PER2. Bioinformatics, immunoprecipitation, GST pull-down, CHX chase assay and western blot and strip to detect the mechanism of PER2 regulation for PD-L1. A humanized immune reconstitution subcutaneous xenograft mouse model was established to investigate the combination therapy efficacy.
Results
In OSCC tissues and cells, PER2 expression was reduced and PD-L1 expression was increased, the expression of PER2 was significantly negatively correlated with PD-L1. In vitro and in vivo experiments demonstrated that PER2 inhibited PD-L1 expression and enhanced T-cell-mediated OSCC cell killing by suppressing the IKK/NF-κB pathway. Mechanistically, PER2 binds to heat shock protein 90 (HSP90) through the PAS1 domain and reduces the interaction of HSP90 with inhibitors of kappa B kinase (IKKs), promoting the ubiquitination of IKKα/β and p65 nuclear translocation to inhibit IKK/NF-κB pathway, thereby suppressing PD-L1 expression. In humanized immune reconstitution subcutaneous xenograft mouse model, it was demonstrated that PER2 targeting combined with anti-PD-L1 treatment improved the inhibition of OSCC growth by promoting CD8 + T-cell infiltration into the tumor.
Conclusions
Our findings reveal the role and mechanism of PD-L1 regulation by PER2 and support the potential clinical application of PER2 targeting in combination with anti-PD-L1 in OSCC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Otolaryngology Head and Neck Surgery, University-Town Hospital of Chongqing Medical University, Chongqing, China.
- Department of Stomatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China cqfyyk@hotmail.com.
ORCID-Profile: Zhiwei Zhang, Kai Yang
Förderung
- Chongqing Talents · Innovation Leading Talents Project
- Natural Science Foundation of Chongqing, China
Zitieren
APA
Zhang, Z., Sun, D., Tang, H., Ren, J., Yin, S., & Yang, K. (2023). PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression. Journal for ImmunoTherapy of Cancer, 11(11), e007627. https://doi.org/10.1136/jitc-2023-007627
Vancouver
Zhang Z, Sun D, Tang H, Ren J, Yin S, Yang K. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007627. doi:10.1136/jitc-2023-007627
BibTeX
@article{Zhang2023,
author = {Zhang, Zhiwei and Sun, Deping and Tang, Hong and Ren, Jie and Yin, Shilin and Yang, Kai},
title = {PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {11},
pages = {e007627},
doi = {10.1136/jitc-2023-007627}
}
EUVIMED